Inhibrx LLC
Biotherapeutics discovery and development
Inhibrx LLC focuses on biologic therapeutic development in areas where there are unmet needs for novel or better drugs, and where the preclinical models clearly demonstrate the potential for success in the clinic. Its model is to license its programs to pharmaceutical and biotech companies for clinical development and commercialization, with no plans to carry out those steps on its own.
More from Archive
More from Scrip
Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.
CEO Robert Michael said AbbVie is positioned strongly to handle current and potentially upcoming tariffs, while committing $10bn to increased US manufacturing sites.
GSK’s antibody-drug conjugate looks set for a blockbuster future in multiple myeloma after an approval in the UK, and the company’s head of oncology says it is already planning for the next generation of therapies.